Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 246

1.

Stromal niche cells protect early leukemic FLT3-ITD+ progenitor cells against first-generation FLT3 tyrosine kinase inhibitors.

Parmar A, Marz S, Rushton S, Holzwarth C, Lind K, Kayser S, Döhner K, Peschel C, Oostendorp RA, Götze KS.

Cancer Res. 2011 Jul 1;71(13):4696-706. doi: 10.1158/0008-5472.CAN-10-4136. Epub 2011 May 5.

PMID:
21546568
[PubMed - indexed for MEDLINE]
Free Article
2.

Sorafenib treatment of FLT3-ITD(+) acute myeloid leukemia: favorable initial outcome and mechanisms of subsequent nonresponsiveness associated with the emergence of a D835 mutation.

Man CH, Fung TK, Ho C, Han HH, Chow HC, Ma AC, Choi WW, Lok S, Cheung AM, Eaves C, Kwong YL, Leung AY.

Blood. 2012 May 31;119(22):5133-43. doi: 10.1182/blood-2011-06-363960. Epub 2012 Feb 24.

PMID:
22368270
[PubMed - indexed for MEDLINE]
Free Article
3.

Crenolanib is active against models of drug-resistant FLT3-ITD-positive acute myeloid leukemia.

Zimmerman EI, Turner DC, Buaboonnam J, Hu S, Orwick S, Roberts MS, Janke LJ, Ramachandran A, Stewart CF, Inaba H, Baker SD.

Blood. 2013 Nov 21;122(22):3607-15. doi: 10.1182/blood-2013-07-513044. Epub 2013 Sep 17.

PMID:
24046014
[PubMed - indexed for MEDLINE]
4.

Mutant FLT3: a direct target of sorafenib in acute myelogenous leukemia.

Zhang W, Konopleva M, Shi YX, McQueen T, Harris D, Ling X, Estrov Z, Quintás-Cardama A, Small D, Cortes J, Andreeff M.

J Natl Cancer Inst. 2008 Feb 6;100(3):184-98. doi: 10.1093/jnci/djm328. Epub 2008 Jan 29.

PMID:
18230792
[PubMed - indexed for MEDLINE]
Free Article
5.

TTT-3002 is a novel FLT3 tyrosine kinase inhibitor with activity against FLT3-associated leukemias in vitro and in vivo.

Ma H, Nguyen B, Li L, Greenblatt S, Williams A, Zhao M, Levis M, Rudek M, Duffield A, Small D.

Blood. 2014 Mar 6;123(10):1525-34. doi: 10.1182/blood-2013-08-523035. Epub 2014 Jan 9.

PMID:
24408321
[PubMed - indexed for MEDLINE]
6.

Phosphoproteome analyses reveal specific implications of Hcls1, p21-activated kinase 1 and Ezrin in proliferation of a myeloid progenitor cell line downstream of wild-type and ITD mutant Fms-like tyrosine kinase 3 receptors.

Habif G, Grasset MF, Kieffer-Jaquinod S, Kuhn L, Mouchiroud G, Gobert-Gosse S.

J Proteomics. 2013 Jan 14;78:231-44. doi: 10.1016/j.jprot.2012.09.009. Epub 2012 Sep 24.

PMID:
23017497
[PubMed - indexed for MEDLINE]
7.

Impact of CXCR4 inhibition on FLT3-ITD-positive human AML blasts.

Jacobi A, Thieme S, Lehmann R, Ugarte F, Malech HL, Koch S, Thiede C, Müller K, Bornhäuser M, Ryser M, Brenner S.

Exp Hematol. 2010 Mar;38(3):180-90. doi: 10.1016/j.exphem.2009.12.003. Epub 2009 Dec 24.

PMID:
20035824
[PubMed - indexed for MEDLINE]
8.

Targeting the leukemia microenvironment by CXCR4 inhibition overcomes resistance to kinase inhibitors and chemotherapy in AML.

Zeng Z, Shi YX, Samudio IJ, Wang RY, Ling X, Frolova O, Levis M, Rubin JB, Negrin RR, Estey EH, Konoplev S, Andreeff M, Konopleva M.

Blood. 2009 Jun 11;113(24):6215-24. doi: 10.1182/blood-2008-05-158311. Epub 2008 Oct 27.

PMID:
18955566
[PubMed - indexed for MEDLINE]
Free PMC Article
9.

Selective FLT3 inhibition of FLT3-ITD+ acute myeloid leukaemia resulting in secondary D835Y mutation: a model for emerging clinical resistance patterns.

Moore AS, Faisal A, Gonzalez de Castro D, Bavetsias V, Sun C, Atrash B, Valenti M, de Haven Brandon A, Avery S, Mair D, Mirabella F, Swansbury J, Pearson AD, Workman P, Blagg J, Raynaud FI, Eccles SA, Linardopoulos S.

Leukemia. 2012 Jul;26(7):1462-70. doi: 10.1038/leu.2012.52. Epub 2012 Feb 22.

PMID:
22354205
[PubMed - indexed for MEDLINE]
Free PMC Article
10.

Bis(1H-indol-2-yl)methanones are effective inhibitors of FLT3-ITD tyrosine kinase and partially overcome resistance to PKC412A in vitro.

Heidel F, Lipka DB, Mirea FK, Mahboobi S, Grundler R, Kancha RK, Duyster J, Naumann M, Huber C, Böhmer FD, Fischer T.

Br J Haematol. 2009 Mar;144(6):865-74. doi: 10.1111/j.1365-2141.2008.07567.x. Epub 2009 Jan 16.

PMID:
19183186
[PubMed - indexed for MEDLINE]
11.

Internal tandem duplications of the FLT3 gene are present in leukemia stem cells.

Levis M, Murphy KM, Pham R, Kim KT, Stine A, Li L, McNiece I, Smith BD, Small D.

Blood. 2005 Jul 15;106(2):673-80. Epub 2005 Mar 29.

PMID:
15797998
[PubMed - indexed for MEDLINE]
Free PMC Article
12.

Irreversible pan-ERBB inhibitor canertinib elicits anti-leukaemic effects and induces the regression of FLT3-ITD transformed cells in mice.

Nordigården A, Zetterblad J, Trinks C, Gréen H, Eliasson P, Druid P, Lotfi K, Rönnstrand L, Walz TM, Jönsson JI.

Br J Haematol. 2011 Oct;155(2):198-208. doi: 10.1111/j.1365-2141.2011.08819.x. Epub 2011 Aug 16.

PMID:
21848891
[PubMed - indexed for MEDLINE]
13.

The FLT3 internal tandem duplication mutation is a secondary target of the aurora B kinase inhibitor AZD1152-HQPA in acute myelogenous leukemia cells.

Grundy M, Seedhouse C, Shang S, Richardson J, Russell N, Pallis M.

Mol Cancer Ther. 2010 Mar;9(3):661-72. doi: 10.1158/1535-7163.MCT-09-1144. Epub 2010 Feb 16.

PMID:
20159992
[PubMed - indexed for MEDLINE]
Free Article
14.

Aberrant expression of CD7 in myeloblasts is highly associated with de novo acute myeloid leukemias with FLT3/ITD mutation.

Rausei-Mills V, Chang KL, Gaal KK, Weiss LM, Huang Q.

Am J Clin Pathol. 2008 Apr;129(4):624-9. doi: 10.1309/NRTX9AKXHR5JBT93.

PMID:
18343790
[PubMed - indexed for MEDLINE]
Free Article
15.

Mechanisms of resistance against PKC412 in resistant FLT3-ITD positive human acute myeloid leukemia cells.

Stölzel F, Steudel C, Oelschlägel U, Mohr B, Koch S, Ehninger G, Thiede C.

Ann Hematol. 2010 Jul;89(7):653-62. doi: 10.1007/s00277-009-0889-1. Epub 2010 Jan 30.

PMID:
20119833
[PubMed - indexed for MEDLINE]
16.

Constitutive activation of Flt3 and STAT5A enhances self-renewal and alters differentiation of hematopoietic stem cells.

Moore MA, Dorn DC, Schuringa JJ, Chung KY, Morrone G.

Exp Hematol. 2007 Apr;35(4 Suppl 1):105-16.

PMID:
17379095
[PubMed - indexed for MEDLINE]
17.

Targeting FLT3 for the treatment of leukemia.

Small D.

Semin Hematol. 2008 Jul;45(3 Suppl 2):S17-21. doi: 10.1053/j.seminhematol.2008.07.007. Review.

PMID:
18760705
[PubMed - indexed for MEDLINE]
Free PMC Article
18.

Terminal myeloid differentiation in vivo is induced by FLT3 inhibition in FLT3/ITD AML.

Sexauer A, Perl A, Yang X, Borowitz M, Gocke C, Rajkhowa T, Thiede C, Frattini M, Nybakken GE, Pratz K, Karp J, Smith BD, Levis M.

Blood. 2012 Nov 15;120(20):4205-14. doi: 10.1182/blood-2012-01-402545. Epub 2012 Sep 25.

PMID:
23012328
[PubMed - indexed for MEDLINE]
Free PMC Article
19.

Emergence of polyclonal FLT3 tyrosine kinase domain mutations during sequential therapy with sorafenib and sunitinib in FLT3-ITD-positive acute myeloid leukemia.

Baker SD, Zimmerman EI, Wang YD, Orwick S, Zatechka DS, Buaboonnam J, Neale GA, Olsen SR, Enemark EJ, Shurtleff S, Rubnitz JE, Mullighan CG, Inaba H.

Clin Cancer Res. 2013 Oct 15;19(20):5758-68. doi: 10.1158/1078-0432.CCR-13-1323. Epub 2013 Aug 22.

PMID:
23969938
[PubMed - indexed for MEDLINE]
20.

Lyn is an important component of the signal transduction pathway specific to FLT3/ITD and can be a therapeutic target in the treatment of AML with FLT3/ITD.

Okamoto M, Hayakawa F, Miyata Y, Watamoto K, Emi N, Abe A, Kiyoi H, Towatari M, Naoe T.

Leukemia. 2007 Mar;21(3):403-10. Epub 2007 Jan 18.

PMID:
17230226
[PubMed - indexed for MEDLINE]

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk